17-Methoxy-20-methyl-5-morpholin-4-yl-1,8,10,20,24,32-hexazapentacyclo[24.2.2.13,7.19,13.114,18]tritriaconta-3(33),4,6,9,11,13(32),14(31),15,17-nonaen-25-one | 1187658-38-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: 17-Methoxy-20-methyl-5-morpholin-4-yl-1,8,10,20,24,32-hexazapentacyclo[24.2.2.13,7.19,13.114,18]tritriaconta-3(33),4,6,9,11,13(32),14(31),15,17-nonaen-25-one
• CAS: 1187658-38-3
• 化学式: C₃₃H₄₃N₇O₃
• 分子量: 585.75
• InChiKey: KNLLHFCJURDHPY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  43
• 可旋转键数：
  2
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  95.1
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• 4-ARYL-2-ANILINO-PYRIMIDINES
  申请人：Buijnsters Peter Jacobus Johannes

  公开号：US20110009404A1

  公开（公告）日：2011-01-13

  The present invention relates to compounds of Formula (Ia) or (Ib), the N-oxide forms, pharmaceutically acceptable addition salts, quaternary amines, stereoisomers, tautomers, racemics, metabolites, prodrugs, hydrates, or solvates thereof, wherein Y 1 , m, n, R 1 ; X 1 ; X 2 ; R 2 ; X 3 ; X 4 ; R 3 ; and R 4 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are kinase inhibitors useful for the treatment of disease states mediated by kinase, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumor growth, rheumatoid arthritis, restenosis and atherosclerosis.
• US8318929B2
  申请人：——

  公开号：US8318929B2

  公开（公告）日：2012-11-27